MedTrace Logo

Haloperidol Prophylaxis in Cardiac Surgery for Patients at Risk for Delirium

NCT01862302 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2016-09-16

No results posted yet for this study

Summary

Will the use of prophylactic Haloperidol for patients undergoing open heart surgery reduce the incidence, duration, and severity of post cardiotomy delirium?

Conditions

  • Postoperative Confusion

Interventions

DRUG

Haloperidol

1mg the night before and 1mg the morning of surgery; OR Haloperidol 2mg the morning of surgery

DRUG

Placebo

1 dose the night before and 1 dose the morning of surgery; OR 2 doses the morning of surgery

Sponsors & Collaborators

Principal Investigators

  • Andre Lamy, MD · McMaster University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-08-31
Primary Completion
2015-09-30
Completion
2016-07-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01862302 on ClinicalTrials.gov